Spots Global Cancer Trial Database for neoplasms, glandular and epithelial
Every month we try and update this database with for neoplasms, glandular and epithelial cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer | NCT00672009 | Prostatic Disea... Genital Neoplas... Urogenital Neop... Genital Disease... Adenocarcinoma Prostatic Neopl... Neoplasms, Glan... Carcinoma | Ixabepilone | - | Cedars-Sinai Medical Center | |
| Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. | NCT01398306 | Carcinoma Carcinoma, Rena... Neuroendocrine ... Carcinoid Tumor Pancreatic Isle... | Blood sampling ... | 18 Years - | University Medical Center Groningen | |
| Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin | NCT00481936 | Neoplasms, Glan... | VB6-845 | 18 Years - | Sesen Bio, Inc. | |
| Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers | NCT01523678 | Ovarian Cancer Endometrial Can... Uterine Cervica... | Filgrastim Paclitaxel Carboplatin | 18 Years - | Belgian Gynaecological Oncology Group | |
| A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma | NCT02993731 | Carcinoma, Panc... | Napabucasin Nab-paclitaxel Gemcitabine | 18 Years - | Sumitomo Pharma America, Inc. | |
| Renal Cell Carcinoma Microenvironment Discovery Project | NCT04005183 | Renal Cell Carc... | 18 Years - | University Health Network, Toronto | ||
| Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
| Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | NCT03769467 | Nasopharyngeal ... Nasopharyngeal ... Epstein-Barr Vi... Epstein-Barr Vi... Epstein-Barr Vi... | tabelecleucel pembrolizumab | 12 Years - | Atara Biotherapeutics | |
| A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | NCT01039948 | Carcinoma, Non-... Lung Neoplasms Lung Cancer Respiratory Tra... | AV-299 + gefiti... Gefitinib | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols | NCT04299880 | Oncology | Napabucasin Nab-paclitaxel Gemcitabine Nivolumab Paclitaxel Irinotecan Leucovorin 5Fluorouracil Bevacizumab | 18 Years - | Sumitomo Pharma America, Inc. | |
| Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial | NCT01995942 | Adenocarcinoma Rectal Diseases Colorectal Neop... Adenocarcinoma,... Carcinoma Neoplasms, Glan... Neoplasms by Hi... Neoplasms Neoplasms, Cyst... Intestinal Neop... Gastrointestina... Digestive Syste... Neoplasms by Si... Digestive Syste... Gastrointestina... Intestinal Dise... | 18 Years - | Royal Marsden NHS Foundation Trust | ||
| Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols | NCT04299880 | Oncology | Napabucasin Nab-paclitaxel Gemcitabine Nivolumab Paclitaxel Irinotecan Leucovorin 5Fluorouracil Bevacizumab | 18 Years - | Sumitomo Pharma America, Inc. | |
| Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | NCT01009593 | Hepatocellular ... Hepatocellular ... Carcinoma, Hepa... Liver Diseases Neoplasms by Hi... Digestive Syste... Carcinoma Liver Neoplasms Neoplasms Neoplasms by Si... Digestive Syste... Adenocarcinoma Neoplasms, Glan... | ABT-869 Sorafenib | 18 Years - | Abbott | |
| Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC) | NCT02112656 | Hepatocellular ... | ThermoDox Dummy infusion | 18 Years - | Imunon | |
| Vorasidenib Expanded Access Program | NCT05592743 | Glioma Recurrence Disease Attribu... Pathologic Proc... Neoplasms, Neur... Neuroectodermal... Neoplasms, Germ... Neoplasms by Hi... Neoplasms Neoplasms, Glan... Neoplasms, Nerv... | Vorasidenib | 12 Years - | Servier | |
| Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer | NCT05388773 | Oropharynx Canc... | therapeutic con... laboratory biom... quality-of-life... intensity-modul... Cisplatin Carboplatin | 18 Years - | University of Pittsburgh | |
| Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED) | NCT00337428 | Neoplasms, Glan... Diphtheria Tetanus Whooping Cough Poliomyelitis | Comparator: Qua... Comparator: Qua... Comparator: REP... Comparator: REP... | 11 Years - 17 Years | Merck Sharp & Dohme LLC | |
| Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer | NCT05297734 | End of Life Cancer | Receive technol... Receive redesig... | 21 Years - | Stanford University | |
| Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer | NCT03562897 | Carcinoma Ovarian Neoplas... Endocrine Gland... Urogenital Neop... Ovarian Disease... Adnexal Disease... Genital Disease... Female Urogenit... Female Urogenit... Endocrine Syste... Gonadal Disorde... Genital Neoplas... Neoplasms, Glan... | Ocoxin-Viusid | 18 Years - | Catalysis SL | |
| Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols | NCT04299880 | Oncology | Napabucasin Nab-paclitaxel Gemcitabine Nivolumab Paclitaxel Irinotecan Leucovorin 5Fluorouracil Bevacizumab | 18 Years - | Sumitomo Pharma America, Inc. | |
| Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
| Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. | NCT01398306 | Carcinoma Carcinoma, Rena... Neuroendocrine ... Carcinoid Tumor Pancreatic Isle... | Blood sampling ... | 18 Years - | University Medical Center Groningen | |
| Low Rectal Cancer Study (MERCURY II) | NCT02005965 | Adenocarcinoma Adenocarcinoma,... Carcinoma Neoplasms, Glan... Neoplasms by Hi... Neoplasms Neoplasms, Cyst... Colorectal Neop... Intestinal Neop... Gastrointestina... Digestive Syste... Neoplasms by Si... Digestive Syste... Gastrointestina... Intestinal Dise... Rectal Diseases | 18 Years - | Royal Marsden NHS Foundation Trust | ||
| BowelScope: Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities | NCT03072472 | Colorectal Neop... Colonic Polyp Adenoma Neoplasia GI Digestive Syste... Intestinal Neop... Neoplasms, Glan... Digestive Disea... Intestinal Dise... Colonic Disease... Rectal Diseases Intestinal Poly... Polyps Pathological Co... | Endocuff Vision | 55 Years - 61 Years | South Tyneside and Sunderland NHS Foundation Trust | |
| Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy | NCT05152927 | Parathyroid Dis... Parathyroid Dys... Parathyroid Neo... Parathyroid Ade... Hypercalcemia Neoplasms, Glan... Endocrine Gland... Adenoma Hyperparathyroi... Hyperparathyroi... | Parathyroid Eye... | 18 Years - | University of California, San Francisco | |
| Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | NCT02909452 | Neoplasms Neoplasms, Glan... Neoplasms by Hi... Bronchial Neopl... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Digestive Syste... Endocrine Gland... Carcinoma, Non-... Lung Diseases Breast Diseases Renal Neoplasm Solid Tumors | Entinostat Pembrolizumab | 18 Years - | Syndax Pharmaceuticals | |
| Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | NCT01009593 | Hepatocellular ... Hepatocellular ... Carcinoma, Hepa... Liver Diseases Neoplasms by Hi... Digestive Syste... Carcinoma Liver Neoplasms Neoplasms Neoplasms by Si... Digestive Syste... Adenocarcinoma Neoplasms, Glan... | ABT-869 Sorafenib | 18 Years - | Abbott | |
| Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer | NCT03562897 | Carcinoma Ovarian Neoplas... Endocrine Gland... Urogenital Neop... Ovarian Disease... Adnexal Disease... Genital Disease... Female Urogenit... Female Urogenit... Endocrine Syste... Gonadal Disorde... Genital Neoplas... Neoplasms, Glan... | Ocoxin-Viusid | 18 Years - | Catalysis SL | |
| DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors | NCT02197169 | Glioblastoma or... | Single intratum... Interferon-gamm... | 18 Years - | DNAtrix, Inc. | |
| Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer | NCT04519151 | Ovarian Neoplas... Carcinoma, Ovar... Neoplasm of Sto... Ovarian Disease... Genital Neoplas... Ovarian Epithel... Urogenital Neop... Neoplasms, Glan... | Pembrolizumab Lenvatinib | 18 Years - | Sheba Medical Center | |
| Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors | NCT01177007 | Liver Neoplasms | TheraSphere, Yt... | 18 Years - | Yale University | |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | NCT03037385 | RET-altered Non... Medullary Thyro... RET-altered Pap... RET-altered Col... RET-altered Sol... Lung Neoplasm Carcinoma, Non-... Thyroid Disease... Thyroid Neoplas... Thyroid Cancer,... Carcinoma, Neur... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Endocrine Syste... Endocrine Gland... Head and Neck N... Adenocarcinoma,... Adenocarcinoma Carcinoma Neoplasms, Glan... Neoplasms by Hi... Neuroendocrine ... Neuroectodermal... Neoplasms, Germ... Neoplasms, Nerv... Colonic Neoplas... Colorectal Neop... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... | pralsetinib (BL... | 18 Years - | Hoffmann-La Roche | |
| A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | NCT01039948 | Carcinoma, Non-... Lung Neoplasms Lung Cancer Respiratory Tra... | AV-299 + gefiti... Gefitinib | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for Colorectal Laterally Spreading Lesions. | NCT04593407 | Neoplasms, Colo... | Endoscopic muco... Endoscopic subm... | 18 Years - 85 Years | Hospital Universitario 12 de Octubre | |
| A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma | NCT04008082 | Carcinoma, Hepa... Carcinoma Neoplasms, Glan... Neoplasms | Lenvatinib | 18 Years - | Eisai Inc. | |
| TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA. | NCT05233098 | Hepatocellular ... | Technetium-99m ... | 21 Years - | Boston Scientific Corporation | |
| TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA. | NCT05233098 | Hepatocellular ... | Technetium-99m ... | 21 Years - | Boston Scientific Corporation | |
| Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) | NCT05935748 | ccRCC Clear Cell Rena... Kidney Cancer Kidney Neoplasm... Renal Cancer Renal Neoplasms Recurrent Renal... Metastatic Rena... Refractory Rena... Advanced Renal ... Carcinoma Neoplasms Carcinoma, Rena... Neoplasms, Glan... Neoplasm by His... Adenocarcinoma Urologic Neopla... Urogenital Neop... Neoplasms by Si... Kidney Diseases Urologic Diseas... | NKT2152 palbociclib sasanlimab | 18 Years - | NiKang Therapeutics, Inc. | |
| Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer | NCT01431391 | Prostatic Neopl... Prostate Cancer Prostatic Adeno... | sipuleucel-T leuprolide acet... | 18 Years - | Dendreon | |
| A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) | NCT01799499 | Non Muscle Inva... | TC-3 hydrogel TC-3 hydrogel TC-3 hydrogel | 21 Years - | UroGen Pharma Ltd. | |
| Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors | NCT02897778 | Neoplasms Neoplasms, Glan... Neoplasms by Hi... Bronchial Neopl... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Digestive Syste... Endocrine Gland... Carcinoma, Non-... Lung Diseases Breast Neoplasm... Breast Diseases Renal Neoplasm Solid Tumors | Entinostat Placebo | 18 Years - | Syndax Pharmaceuticals | |
| Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma | NCT04124198 | Oropharynx Canc... Oropharynx Squa... Carcinoma, Squa... Carcinoma Oropharyngeal N... Neoplasms, Squa... Neoplasms, Glan... Neoplasms by Hi... Pharyngeal Neop... Otorhinolaryngo... Head and Neck N... Neoplasms by Si... Otorhinolaryngo... Pharyngeal Dise... Papillomavirus ... Virus Diseases DNA Virus Infec... Tumor Virus Inf... Quality of Life | Intensity-Modul... Cisplatin Nimorazole. Transoral Robot... | 18 Years - | Rigshospitalet, Denmark | |
| Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
| HR Versus RFA for HCC in Patients With PHT | NCT02192671 | Carcinoma, Hepa... Liver Neoplasms Neoplasms, Glan... | Hepatic Resecti... Radiofrequency ... | 18 Years - 75 Years | Guangxi Medical University | |
| Low Rectal Cancer Study (MERCURY II) | NCT02005965 | Adenocarcinoma Adenocarcinoma,... Carcinoma Neoplasms, Glan... Neoplasms by Hi... Neoplasms Neoplasms, Cyst... Colorectal Neop... Intestinal Neop... Gastrointestina... Digestive Syste... Neoplasms by Si... Digestive Syste... Gastrointestina... Intestinal Dise... Rectal Diseases | 18 Years - | Royal Marsden NHS Foundation Trust | ||
| Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites | NCT00326885 | Malignant Ascit... | catumaxomab | 18 Years - | Neovii Biotech | |
| Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma | NCT04124198 | Oropharynx Canc... Oropharynx Squa... Carcinoma, Squa... Carcinoma Oropharyngeal N... Neoplasms, Squa... Neoplasms, Glan... Neoplasms by Hi... Pharyngeal Neop... Otorhinolaryngo... Head and Neck N... Neoplasms by Si... Otorhinolaryngo... Pharyngeal Dise... Papillomavirus ... Virus Diseases DNA Virus Infec... Tumor Virus Inf... Quality of Life | Intensity-Modul... Cisplatin Nimorazole. Transoral Robot... | 18 Years - | Rigshospitalet, Denmark | |
| A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients With Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma | NCT05494866 | CYP3A Inhibitor Advanced Stage ... Pancreatic Canc... Pancreatic Aden... Pancreatic Neop... | Cobicistat Oral... Gemcitabin Nab paclitaxel | 18 Years - | German Cancer Research Center | |
| TheraSphere With Durvalumab and Tremelimumab for HCC | NCT05063565 | Hepatocellular ... | TheraSphere Y-9... Durvalumab (Imf... Tremelimumab im... | 18 Years - | Boston Scientific Corporation | |
| Vorasidenib Expanded Access Program | NCT05592743 | Glioma Recurrence Disease Attribu... Pathologic Proc... Neoplasms, Neur... Neuroectodermal... Neoplasms, Germ... Neoplasms by Hi... Neoplasms Neoplasms, Glan... Neoplasms, Nerv... | Vorasidenib | 12 Years - | Servier | |
| GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer | NCT02759588 | Ovarian Cancer Peritoneal Carc... Fallopian Tube ... | GL-ONC1 alone, ... | 21 Years - | Genelux Corporation | |
| A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients With Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma | NCT05494866 | CYP3A Inhibitor Advanced Stage ... Pancreatic Canc... Pancreatic Aden... Pancreatic Neop... | Cobicistat Oral... Gemcitabin Nab paclitaxel | 18 Years - | German Cancer Research Center | |
| Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma | NCT04974866 | Carcinoma, Aden... | EGFR-TK Inhibit... | 18 Years - 90 Years | Qingdao Central Hospital | |
| Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | NCT03769467 | Nasopharyngeal ... Nasopharyngeal ... Epstein-Barr Vi... Epstein-Barr Vi... Epstein-Barr Vi... | tabelecleucel pembrolizumab | 12 Years - | Atara Biotherapeutics | |
| A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer | NCT02753127 | Colorectal Canc... | Napabucasin Fluorouracil Leucovorin Irinotecan Bevacizumab | 18 Years - | Sumitomo Pharma America, Inc. | |
| Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025) | NCT00325130 | Neoplasms, Glan... Diphtheria Tetanus Whooping Cough Meningitis | Comparator: Qua... Comparator: Men... Comparator: Ada... Comparator: Men... Comparator: Ada... | 11 Years - 17 Years | Merck Sharp & Dohme LLC | |
| Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin | NCT00481936 | Neoplasms, Glan... | VB6-845 | 18 Years - | Sesen Bio, Inc. | |
| Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors | NCT01215578 | Neuroendocrine ... Pancreatic Neop... Advanced Diseas... Sunitinib | Sutent | 18 Years - | Assistance Publique - Hôpitaux de Paris |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
